Opinion|Videos|November 29, 2024
Safety of Advanced Therapies in Clinical Trials vs Real World Experience
Lisa J. Faia, MD asks the panel about their concerns regarding the safety of newer agents for the broad array of retinal vascular diseases, highlighting the similarities and differences between clinical trial outcomes and real-world results.
Advertisement
Episodes in this series
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape
Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA requires NAION warning across the GLP-1 receptor agonist class
2
Longer anti-VEGF intervals in AMD, BRVO, and DME: 3 clinical cases
3
Tenpoint Therapeutics opens telehealth access to Yuvezzi for adults with presbyopia
4
The interplay between cardiac disease and the eye
5